Efficacy and safety of MPC-7869 (R-flurbiprofen), a selective ab42-lowering agent, in mild Alzheimer's disease (AD): Results of a 12-month Phase 2 trial and 1-year follow-on study - Black, S; Wilcock, G; Haworth, J; Hendrix, S; Zavitz, K; Christensen, D; Binger, M; Bass, S; Laughlin, M; Swabb, E (2006)